Drug Information Assn. is sponsoring workshop on new law Dec. 3-4 at the Hyatt Regency Hotel in Princeton, NJ. Agenda includes Sen. Hatch (R-Utah), House Health and Environment subcmte. counsel John McLaughlin, FDA Generic Drugs Div. Director Marvin Seife, MD, and Generic Pharmaceutical Industry Assn. President William Haddad. Registrations are still open.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.